Arctic Bioscience AS (OSL:ABS)

Norway flag Norway · Delayed Price · Currency is NOK
3.400
-0.060 (-1.73%)
Apr 28, 2026, 3:54 PM CET
-24.44%
Market Cap 93.27M
Revenue (ttm) 45.90M
Net Income (ttm) -43.36M
Shares Out 26.96M
EPS (ttm) -1.66
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 8,200
Average Volume 13,161
Open 3.390
Previous Close 3.460
Day's Range 3.390 - 3.400
52-Week Range 2.500 - 4.950
Beta 1.09
RSI 51.62
Earnings Date May 7, 2026

About Arctic Bioscience AS

Arctic Bioscience AS, a clinical-stage biotechnology company, engages in developing and commercializing pharmaceutical and nutraceutical ingredients based on bioactive marine compounds in Norway, the United States, Europe, and Asia Pacific. The company is developing HRO350, a novel oral drug which is in phase IIb for the treatment of mild-to-moderate psoriasis. It also sells nutraceuticals as intermediary and finished goods products under the ROMEGA brand name. Arctic Bioscience AS was incorporated in 2011 and is headquartered in Ørsta, Norway. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2011
Employees 22
Stock Exchange Oslo Børs
Ticker Symbol ABS
Full Company Profile

Financial Performance

In 2024, Arctic Bioscience AS's revenue was 44.40 million, an increase of 31.55% compared to the previous year's 33.76 million. Losses were -47.93 million, 5.31% more than in 2023.

Financial Statements

News

Arctic Bioscience AS Earnings Call Transcript: Q4 2024

Record 2024 sales and margin growth were driven by strong nutraceutical performance, especially in Europe, and supported by new funding and cost reductions. Awaiting key 12-month clinical data for HRO350, with further expansion planned in Asia and Europe.

1 year ago - Transcripts

Arctic Bioscience AS Transcript: Study Result

The phase IIb HeROPA trial for HRO350 in mild to moderate psoriasis did not meet its primary endpoint at 26 weeks due to a high placebo response, though no safety concerns were observed. Long-term efficacy and safety will be assessed at 52 weeks, with future development plans on hold pending these results.

1 year ago - Transcripts

Arctic Bioscience AS Earnings Call Transcript: H1 2024

H1 2024 saw stable revenues, strong gross margin, and continued investment in pharma R&D, with Nutra sales growth in Norway and China. The HEROPA phase IIB trial is fully recruited, with a key data readout expected late September/early October 2024.

1 year ago - Transcripts